disability

At the time of my MS diagnosis I was a full-time graduate student with plans to obtain a joint Masters of Public Administration/Juris Doctor degree. After six years as a stay-at-home mom and military spouse, I was anxious to complete this next stage of my education and return to…

  When thinking about multiple sclerosis (MS), it’s important to remember there are four distinct types of the disease. Most of you well know this, so I’ll just mention them here: relapsing-remitting MS (RRMS); secondary progressive MS; primary progressive MS, and clinically isolated syndrome. (Anyone needing or wishing more information…

Cyclophosphamide (CPM) may delay the progression of disability in the first years of secondary progressive multiple sclerosis (SPMS), but patients must take it for two years — and many are unlikely to tolerate it for that long. The study, “Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive…

Recently published data from three Phase 3 trials of Ocrevus (ocrelizumab) show that the investigational drug does what no other therapy has achieved so far — working to prevent disease in both relapsing and primary progressive (PP) forms of multiple sclerosis (MS). Publications in the New England Journal…

Despite recent studies showing that treatment with Ampyra (Fampyra in Europe; fampridine) improves both walking speed and ability, and offers psychological benefits to patients with multiple sclerosis (MS), the Scottish Medicines Consortium (SMC) recently decided to not recommend the drug for use on the National Health Service (NHS) in Scotland.

The British government announced on Oct. 31 that a new Personal Support Package will be available for people with health disabilities, such as multiple sclerosis (MS), ensuring they receive personalized health and employment support. A Green Paper – a government document for consultation – is available online to open…

ABLE Accounts and Amendments In my previous column, I introduced the exciting new program for people with disabilities, called the ABLE Act (Achieving a Better Life Experience Act). The final bill, signed into law in 2014, deviated substantially from the original proposal and that needs to…

RedHill Biopharma recently announced that it has received a Notice of Allowance from the Japan Patent Office for a new patent covering RHB-104 as a potential treatment of multiple sclerosis (MS). Once granted, the patent will be valid until 2032. The European Patent Office also recently approved a patent application for the drug with this…

Lemtrada (alemtuzumab) was seen to help reverse disability among patients with relapsing forms of multiple sclerosis (MS) in relatively early stages of the disease, researchers report. The study, “Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients,” published in the journal Neurology, supports the idea that treatment…

Disability from multiple sclerosis develops, on average, within 10 years of diagnosis. Financial catastrophe was often the consequence, until Congress passed the Achieving a Better Life Experience Act (ABLE Act) — signed into law on Dec. 19, 2014, by President Obama. This act allows you or anyone to…

Results from the ORATORIO trial, exploring Ocrevus (ocrelizumab) for the treatment of primary progressive forms of multiple sclerosis (MS), showed that the drug stopped disease progression for more than two years in more patients than a placebo. The findings, a highlight at the European Committee for Treatment and Research…

Novartis recently announced positive results from the ACROSS study, which is assessing the clinical effect of Gilenya (fingolimod) in 10-year disability outcomes in people with relapsing-remitting multiple sclerosis (RRMS). The results were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Sept. 14-17 in London. The ACROSS study…

A five-year study comparing the efficacy of different treatments for relapsing-remitting multiple sclerosis (RRMS) found that, in general, Lemtrada (alemtuzumab) and Tysabri (natalizumab) are more effective as therapies than Gilenya (fingolimod) and interferon β. Study results were presented in an oral presentation, “Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon β-1a,”…

You don’t see people with disabilities very often in television ads.  And when you do, the person with the handicap is usually playing a secondary role or the ad uses the disabled person for an emotional appeal.  It’s not real-life.  It’s not us. So, a tip of my hat to…

A pilot study exploring the antioxidant lipoic acid in patients with secondary progressive multiple sclerosis (SPMS) demonstrated that treatment for two years reduced the speed of brain tissue loss and improved the patients’ walking speed. The surprising finding was presented during the “New directions in progressive MS research”…

Biogen and AbbVie presented positive new post-hoc analysis from the pivotal DECIDE clinical trial, which showed that a significantly larger number of relapsing multiple sclerosis (RMS) patients treated with Zinbryta (daclizumab) had no evidence of disease activity (NEDA) compared to those treated with Avonex (interferon beta-1a). The data were given at the recent 32nd Congress of the European…

A high fraction of patients with multiple sclerosis (MS) who underwent a transplant with their own bone marrow stem cells after immunosupression therapy, show no signs of disease activity after treatment, according to a new study. The results were presented in a talk, “Clinical experience in aggressive multiple sclerosis treatment with…

Two presentations at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress, now underway in London, underscored the value of measures of neurodegeneration in the eye in predicting a patient’s future disability. Peter Calabresi with the Johns Hopkins School of Medicine opened the session with the presentation, “Tools for…

Previous studies have pointed toward certain lifestyle factors such as nutrition, sedentary behavior, and stress as possible key determinants in multiple sclerosis (MS) progression but few studies have been dedicated to learning more about the impact of lifestyle risk factors on patient disability and disease progression. A recent study supports the…

A new video series for multiple sclerosis patients in the U.S. looks to help them better understand the complex legal and planning issues they face. The series, put together by the National Academy of Elder Law Attorneys (NAELA) and Stetson University College of Law, in consultation with the National Multiple Sclerosis Society, is…

Despite the existence of several disease-modifying drugs for people with relapsing-remitting multiple sclerosis (RRMS), patients’ satisfaction plays a critical role in their adherence to treatment. Improving adherence should be a major concern in the clinic to prevent patients from evolving to more debilitating stages of the disease. A team of researchers in Germany report that side…

A retrospective study of vitamin D status and disability progression in multiple sclerosis patients — using real-life, clinical data from a large and varied group — found no  correlation between the two, although vitamin D levels may predict the occurrence of relapses in some patients. But these findings may have been limited by the lower doses of daily vitamin…

Helius Medical Technologies announced results of a pilot study, demonstrating the benefits of PoNS Therapy — a combination of the investigational Portable Neuromodulation Stimulator (PoNS) device with physical therapy — in patients with advanced multiple sclerosis (MS). Specifically, the treatment was seen to improve both patients’ quality of life, and physical and…

Researchers at the Swedish Neuroscience Institute in Washington and Novartis Pharma revealed that Gilenya (fingolimod) induced a consistent and significant reduction in disease activity in patients with relapsing-remitting multiple sclerosis (RRMS). The results were recently presented at the June 1-4 Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual…

Researchers who looked at manifestations of loneliness found that the burden of loneliness is much higher in multiple sclerosis (MS) patients when compared to healthy people. The study, “Loneliness in Multiple Sclerosis: Putative Antecedents and Manifestations,” was recently presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) June…

People with primary progressive multiple sclerosis (PPMS) are usually older and more disabled than those with relapsing-remitting MS, researchers at Washington University reported. The team is studying demographic and clinical characteristics of PPMS patients enrolled in the NARCOMS registry, to better understand their unmet needs and possibly improve research into potential treatments. The study, “…

A new study suggests a strong association in multiple sclerosis (MS) patients between high levels of fatigue and mental health, quality of life (QoL), and the ability to move about and participate in daily activities, although disability is not related to fatigue levels.  These findings are of importance and highlight the…

Biogen reported new data describing the effectiveness of Tecfidera (dimethyl fumarate) in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients in a recent presentation at the 68th annual meeting of the American Academy of Neurology (AAN). The conference, taking place in Vancouver, Canada, runs through April 21. Tecfidera is an…

Potentially groundbreaking research by the Tisch Multiple Sclerosis Research Center of New York (MSRCNY) will be presented on April 19 at the 68th American Academy of Neurology (AAN) Annual Meeting taking place in Vancouver, Canada. Dr. Saud A. Sadiq, director and chief research scientist at the Tisch center, will present results of a…

A systematic review of existing medical literature on multiple sclerosis (MS) could shed light on MS causes and predictors for disease progression, and on lifestyle changes — ranging from vitamin D intake to weight loss — that might reduce a person’s risk. The report, “Factors associated with onset, relapses…